What is HC Wainwright’s Forecast for Alector Q1 Earnings?

Alector, Inc. (NASDAQ:ALEC) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Alector in a research note issued to investors on Tuesday, November 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Alector’s Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.66) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.39) EPS.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.10. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The company had revenue of $15.34 million during the quarter, compared to analyst estimates of $16.33 million.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a research note on Tuesday. Morgan Stanley lowered Alector from an “equal weight” rating to an “underweight” rating and lowered their target price for the stock from $10.00 to $3.00 in a report on Tuesday. Finally, BTIG Research lowered their price objective on shares of Alector from $16.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat.com, Alector has an average rating of “Moderate Buy” and an average price target of $14.00.

Alector Price Performance

ALEC opened at $2.55 on Thursday. The business has a 50 day moving average price of $4.75 and a two-hundred day moving average price of $5.02. The company has a market capitalization of $249.23 million, a price-to-earnings ratio of -1.50 and a beta of 0.66. Alector has a 1-year low of $2.37 and a 1-year high of $8.90.

Insider Activity at Alector

In related news, CEO Arnon Rosenthal sold 26,499 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now owns 1,948,746 shares in the company, valued at approximately $9,509,880.48. This represents a 1.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sara Kenkare-Mitra sold 13,926 shares of Alector stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $67,958.88. Following the transaction, the insider now owns 291,715 shares in the company, valued at approximately $1,423,569.20. The trade was a 4.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,722 shares of company stock worth $232,883 in the last quarter. 9.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alector

Several hedge funds have recently bought and sold shares of ALEC. Vanguard Group Inc. grew its stake in Alector by 12.0% during the 1st quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company’s stock valued at $29,574,000 after acquiring an additional 526,037 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in Alector by 18.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,017,687 shares of the company’s stock valued at $4,742,000 after purchasing an additional 159,111 shares in the last quarter. Geode Capital Management LLC increased its stake in Alector by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,903,942 shares of the company’s stock valued at $8,874,000 after buying an additional 148,357 shares during the period. Acadian Asset Management LLC lifted its position in Alector by 32.8% in the 2nd quarter. Acadian Asset Management LLC now owns 590,662 shares of the company’s stock worth $2,681,000 after buying an additional 146,015 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Alector by 1.0% during the 3rd quarter. FMR LLC now owns 14,595,014 shares of the company’s stock valued at $68,013,000 after buying an additional 137,794 shares during the period. 85.83% of the stock is owned by hedge funds and other institutional investors.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.